Medicine

Contact Us School of Medicine
Level 1
Trinity Biomedical Sciences Institute
Trinity College
152-160 Pearse Street
Dublin 2

View the contact page for more contact and location information

medadmin@tcd.ie
Professor Patrick Forde

Professor Patrick Forde

Patrick Prendergast Professor of Immuno-, Surgery

Biography

Prof. Patrick Forde is Prendergast Professor of Immuno-Oncology at Trinity College Dublin and Consultant Medical Oncologist at St. James Hospital Dublin as well as a professor at Johns Hopkins University. He has led the development of immunotherapy for surgically resectable lung cancer from initial concept to worldwide use, initially exploring the role of single agent anti-PD-1 as neoadjuvant therapy and later as principal investigator of the CheckMate 816 trial which led to the approval internationally of neoadjuvant chemo-immunotherapy for stage II-III lung cancer. Long term follow up from this study showed that just 3 doses of immunotherapy before surgery significantly improved long term survival for patients with lung cancer. He leads several translational efforts to optimize the treatment of lung cancer including the global platform neoadjuvant immunotherapy trial, NeoCOAST-2, exploring novel immunotherapy combinations prior to surgery for lung cancer.

Publications and Further Research Outputs

  • Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N;, Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer, New England Journal of Medicine, 2025Journal Article, 2025, DOI
  • Cappelli, L.C., Bingham, C.O., Forde, P.M., Anagnostou, V., Brahmer, J., Lipson, E.J., Mammen, J., Schollenberger, M., Shah, A.A., Darrah, E., Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis, RMD Open, 8, (2), 2022Journal Article, 2022, DOI
  • Ricciuti, B., Wang, X., Alessi, J.V., Rizvi, H., Mahadevan, N.R., Li, Y.Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N.I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V.R., Leonardi, G.C., Plodkowski, A.J., Gupta, H., Cherniack, A.D., Tolstorukov, M.Y., Sharma, B., Felt, K.D., Gainor, J.F., Ravi, A., Getz, G., Schalper, K.A., Henick, B., Forde, P., Anagnostou, V., Jänne, P.A., Van Allen, E.M., Nishino, M., Sholl, L.M., Christiani, D.C., Lin, X., Rodig, S.J., Hellmann, M.D., Awad, M.M., Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels, JAMA Oncology, 8, (8), 2022, p1160-1168Journal Article, 2022, DOI
  • Rosner, S., Liu, C., Forde, P.M., Hu, C., Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis, JTO Clinical and Research Reports, 3, (9), 2022Journal Article, 2022, DOI
  • Rosner, S., Forde, P.M., Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC, Journal of Thoracic Oncology, 17, (4), 2022, p503-509Journal Article, 2022, DOI
  • Liang, W., Cai, K., Cao, Q., Chen, C., Chen, H., Chen, J., Chen, K.-N., Chen, Q., Chu, T., Dong, Y., Fan, J., Fang, W., Fu, J., Fu, X., Gao, S., Ge, D., Geng, G., Geng, Q., He, J., Hu, J., Hu, J., Hu, W.-D., Jiang, F., Jiang, T., Jiao, W., Li, H.-C., Li, Q., Li, S., Li, S., Li, X., Liao, Y.-D., Liu, C., Liu, H., Liu, Y., Lu, Z., Luo, Q., Ma, H., Pan, X., Qiao, G., Ren, S., Shen, W., Song, Y., Sun, D., Wang, G., Wang, J., Wang, M., Wang, Q., Wang, W.-X., Wei, L., Wu, M., Wu, N., Xia, H., Xu, S.-D., Yang, F., Yang, K., Yang, Y., Yu, F., Yu, Z.-T., Yue, D.-S., Zhang, L., Zhang, W., Zhang, Z., Zhao, G., Zhao, J., Zhao, X., Zhou, C., Zhou, Q., Zhu, K., Zhu, Y., Hida, T., Dempke, W.C.M., Rossi, A., de Perrot, M., Ramirez, R.A., Provencio, M., Lee, J.M., Passaro, A., Spaggiari, L., Spicer, J., Girard, N., Forde, P.M., Mok, T.S.K., Cascone, T., He, J., International expert consensus on immunotherapy for early-stage non-small cell lung cancer, Translational Lung Cancer Research, 11, (9), 2022, p1742-1762Journal Article, 2022, DOI
  • Hsu, M.L., Murray, J.C., Psoter, K.J., Zhang, J., Barasa, D., Brahmer, J.R., Ettinger, D.S., Forde, P.M., Hann, C.L., Lam, V.K., Levy, B., Marrone, K.A., Patel, T., Peterson, V., Sagorsky, S., Turner, M., Anagnostou, V., Naidoo, J., Feliciano, J.L., Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy, Oncologist, 27, (11), 2022, p971-981Journal Article, 2022, DOI
  • Friedlaender, A., Naidoo, J., Luigi Banna, G., Metro, G., Forde, P., Addeo, A., Corrigendum to "Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC" [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350)), Cancer Treatment Reviews, 104, 2022Journal Article, 2022, DOI
  • Guo, M.Z., Murray, J.C., Ghanem, P., Voong, K.R., Hales, R.K., Ettinger, D., Lam, V.K., Hann, C.L., Forde, P.M., Brahmer, J.R., Levy, B.P., Feliciano, J.L., Marrone, K.A., Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer, Clinical Lung Cancer, 23, (7), 2022, p620-629Journal Article, 2022, DOI
  • Gridelli, C., Peters, S., Mok, T., Forde, P.M., Reck, M., Attili, I., de Marinis, F., First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology, ESMO Open, 7, (1), 2022Journal Article, 2022, DOI
  • Huang, P., Illei, P.B., Franklin, W., Wu, P.-H., Forde, P.M., Ashrafinia, S., Hu, C., Khan, H., Vadvala, H.V., Shih, I.-M., Battafarano, R.J., Jacobs, M.A., Kong, X., Lewis, J., Yan, R., Chen, Y., Housseau, F., Rahmim, A., Fishman, E.K., Ettinger, D.S., Pienta, K.J., Wirtz, D., Brock, M.V., Lam, S., Gabrielson, E., Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation, Cancers, 14, (17), 2022Journal Article, 2022, DOI
  • Hong, D.S., Rixe, O., Chiu, V.K., Forde, P.M., Dragovich, T., Lou, Y., Nayak-Kapoor, A., Leidner, R., Atkins, J.N., Collaku, A., Fox, F.E., Marshall, M.A., Olszanski, A.J., Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors, Clinical Cancer Research, 28, (3), 2022, p479-488Journal Article, 2022, DOI
  • Valsamo Anagnostou, Blair V. Landon, Jamie E. Medina, Patrick Forde, Victor E. Velculescu, Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy, Science Translational Medicine, 2022Journal Article, 2022, DOI
  • A. S. Mansfield, Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, E. P. Mitchell, J. J. Wright, N. Takebe, E. Sharon, D. Hovelson, S. Tomlins, J. Zeng, K. Poorman, N. Malik, R. J. Gray, S. Li, L. M. McShane, L. V. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O"Dwyer, A. P. Chen, K. T. Flaherty, Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial, npj Precision Oncology, 2022Journal Article, 2022, DOI
  • Gerber, D.E., Singh, H., Larkins, E., Ferris, A., Forde, P.M., Selig, W., Basu Roy, U., A New Approach to Simplifying and Harmonizing Cancer Clinical Trials - Standardizing Eligibility Criteria, JAMA Oncology, 8, (9), 2022, p1333-1339Journal Article, 2022, DOI
  • Liang, K.-L., Tackett, S., Myers, S., Brahmer, J.R., Browner, I.S., Ettinger, D.S., Forde, P.M., Hales, R.K., Hann, C.L., Lam, V.K., Marrone, K.A., Patel, T., Peterson, V., Sagorsky, S., Turner, M., Voong, K.R., Naidoo, J., Feliciano, J.L., An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis, Current Oncology, 29, (6), 2022, p4342-4353Journal Article, 2022, DOI
  • Shaikh, F.Y., Gills, J.J., Mohammad, F., White, J.R., Stevens, C.M., Ding, H., Fu, J., Tam, A., Blosser, R.L., Domingue, J.C., Larman, T.C., Chaft, J.E., Spicer, J.D., Reuss, J.E., Naidoo, J., Forde, P.M., Ganguly, S., Housseau, F., Pardoll, D.M., Sears, C.L., Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors, Cancer Immunology, Immunotherapy, 71, (10), 2022, p2405-2420Journal Article, 2022, DOI
  • Shah, P.P., Franke, J.L., Medikonda, R., Jackson, C.M., Srivastava, S., Choi, J., Forde, P.M., Brahmer, J.R., Ettinger, D.S., Feliciano, J.L., Levy, B.P., Marrone, K.A., Naidoo, J., Redmond, K.J., Kleinberg, L.R., Lim, M., Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy, Journal of Neurosurgery, 136, (1), 2022, p56-66Journal Article, 2022, DOI
  • Forde, P.M., Spicer, J., Girard, N., Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply, The New England journal of medicine, 387, (6), 2022, p572-573Journal Article, 2022, DOI
  • Forde, P.M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M.M., Felip, E., Broderick, S.R., Brahmer, J.R., Swanson, S.J., Kerr, K., Wang, C., Ciuleanu, T.-E., Saylors, G.B., Tanaka, F., Ito, H., Chen, K.-N., Liberman, M., Vokes, E.E., Taube, J.M., Dorange, C., Cai, J., Fiore, J., Jarkowski, A., Balli, D., Sausen, M., Pandya, D., Calvet, C.Y., Girard, N., Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer, New England Journal of Medicine, 386, (21), 2022, p1973-1985Journal Article, 2022, DOI
  • Tarhini, A.A., Eads, J.R., Moore, K.N., Tatard-Leitman, V., Wright, J., Forde, P.M., Ferris, R.L., Neoadjuvant immunotherapy of locoregionally advanced solid tumors, Journal for ImmunoTherapy of Cancer, 10, (8), 2022Journal Article, 2022, DOI
  • Hwang, M., Canzoniero, J.V., Rosner, S., Zhang, G., White, J.R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., Niknafs, N., Zhang, J., Smith, K.N., Sivapalan, L., Chaft, J.E., Reuss, J.E., Marrone, K., Murray, J.C., Li, Q.K., Lam, V., Levy, B.P., Hann, C., Velculescu, V.E., Brahmer, J.R., Forde, P.M., Seiwert, T., Anagnostou, V., Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy, Journal for ImmunoTherapy of Cancer, 10, (6), 2022Journal Article, 2022, DOI
  • Chaft, J.E., Shyr, Y., Sepesi, B., Forde, P.M., Preoperative and Postoperative Systemic Therapy for Operable Non"Small-Cell Lung Cancer, Journal of Clinical Oncology, 40, (6), 2022, p546-555Journal Article, 2022, DOI
  • Kok, P.S., Forde, P.M., Hughes, B., Sun, Z., Brown, C., Ramalingam, S., Cook, A., Lesterhuis, W.J., Yip, S., O'Byrne, K., Pavlakis, N., Brahmer, J., Anagnostou, V., Ford, K., Fitzpatrick, K., Bricker, A., Cummins, M.M., Stockler, M., Nowak, A.K., Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial, BMJ Open, 12, (1), 2022Journal Article, 2022, DOI
  • Friedlaender, A., Naidoo, J., Banna, G.L., Metro, G., Forde, P., Addeo, A., Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC, Cancer Treatment Reviews, 104, 2022Journal Article, 2022, DOI
  • Scott, S.C., Shao, X.M., Niknafs, N., Balan, A., Pereira, G., Marrone, K.A., Lam, V.K., Murray, J.C., Feliciano, J.L., Levy, B.P., Ettinger, D.S., Hann, C.L., Brahmer, J.R., Forde, P.M., Karchin, R., Naidoo, J., Anagnostou, V., Sex-specific differences in immunogenomic features of response to immune checkpoint blockade, Frontiers in Oncology, 12, 2022Journal Article, 2022, DOI
  • Govindan, R., Aggarwal, C., Antonia, S.J., Davies, M., Dubinett, S.M., Ferris, A., Forde, P.M., Garon, E.B., Goldberg, S.B., Hassan, R., Hellmann, M.D., Hirsch, F.R., Johnson, M.L., Malik, S., Morgensztern, D., Neal, J.W., Patel, J.D., Rimm, D.L., Sagorsky, S., Schwartz, L.H., Sepesi, B., Herbst, R.S., Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma, Journal for ImmunoTherapy of Cancer, 10, (5), 2022Journal Article, 2022, DOI
  • Schad, S.E., Chow, A., Mangarin, L., Pan, H., Zhang, J., Ceglia, N., Caushi, J.X., Malandro, N., Zappasodi, R., Gigoux, M., Hirschhorn, D., Budhu, S., Amisaki, M., Arniella, M., Redmond, D., Chaft, J., Forde, P.M., Gainor, J.F., Hellmann, M.D., Balachandran, V., Shah, S., Smith, K.N., Pardoll, D., Elemento, O., Wolchok, J.D., Merghoub, T., Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions, Journal of Experimental Medicine, 219, (6), 2022Journal Article, 2022, DOI
  • Mansfield, A.S., Brown, R.J., Sammon, C., Daumont, M.J., McKenna, M., Sanzari, J.K., Forde, P.M., The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review, JTO Clinical and Research Reports, 3, (5), 2022Journal Article, 2022, DOI
  • Mathios, D., Johansen, J.S., Cristiano, S., Medina, J.E., Phallen, J., Larsen, K.R., Bruhm, D.C., Niknafs, N., Ferreira, L., Adleff, V., Chiao, J.Y., Leal, A., Noe, M., White, J.R., Arun, A.S., Hruban, C., Annapragada, A.V., Jensen, S.Ø., Ørntoft, M.-B.W., Madsen, A.H., Carvalho, B., de Wit, M., Carey, J., Dracopoli, N.C., Maddala, T., Fang, K.C., Hartman, A.-R., Forde, P.M., Anagnostou, V., Brahmer, J.R., Fijneman, R.J.A., Nielsen, H.J., Meijer, G.A., Andersen, C.L., Mellemgaard, A., Bojesen, S.E., Scharpf, R.B., Velculescu, V.E., Detection and characterization of lung cancer using cell-free DNA fragmentomes, Nature Communications, 12, (1), 2021Journal Article, 2021, DOI
  • Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N. Smith, Archana Balan, James R. White, Christopher Cherry, I. K. Ashok Sivakumar, Xiaoshan M. Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B. Illei, Drew M. Pardoll, Rachel Karchin, Victor E. Velculescu, Julie R. Brahmer, Suresh S. Ramalingam, Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial, Nature Medicine, 27, (11), 2021, p1910--1920Journal Article, 2021, DOI
  • Friedes, C., Chakrabarti, T., Olson, S., Prichett, L., Brahmer, J.R., Forde, P.J., Voong, R.K., Marrone, K.A., Lam, V.K., Hann, C.L., Broderick, S.R., Battafarano, R.J., Ha, J.S., Bush, E.L., Yang, S.C., Hales, R.K., Feliciano, J.L., Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy, Lung Cancer, 154, 2021, p36-43Journal Article, 2021, DOI
  • Caushi, J.X., Zhang, J., Ji, Z., Vaghasia, A., Zhang, B., Hsiue, E.H.-C., Mog, B.J., Hou, W., Justesen, S., Blosser, R., Tam, A., Anagnostou, V., Cottrell, T.R., Guo, H., Chan, H.Y., Singh, D., Thapa, S., Dykema, A.G., Burman, P., Choudhury, B., Aparicio, L., Cheung, L.S., Lanis, M., Belcaid, Z., El Asmar, M., Illei, P.B., Wang, R., Meyers, J., Schuebel, K., Gupta, A., Skaist, A., Wheelan, S., Naidoo, J., Marrone, K.A., Brock, M., Ha, J., Bush, E.L., Park, B.J., Bott, M., Jones, D.R., Reuss, J.E., Velculescu, V.E., Chaft, J.E., Kinzler, K.W., Zhou, S., Vogelstein, B., Taube, J.M., Hellmann, M.D., Brahmer, J.R., Merghoub, T., Forde, P.M., Yegnasubramanian, S., Ji, H., Pardoll, D.M., Smith, K.N., Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (Nature, (2021), 596, 7870, (126-132), 10.1038/s41586-021-03752-4), Nature, 598, (7881), 2021, pE1Journal Article, 2021, DOI
  • Naidoo, J., Reuss, J.E., Suresh, K., Feller-Kopman, D., Forde, P.M., Mehta Steinke, S., Rock, C., Johnson, D.B., Nishino, M., Brahmer, J.R., Immune-related (IR)-pneumonitis during the COVID-19 pandemic: Multidisciplinary recommendations for diagnosis and management, Journal for ImmunoTherapy of Cancer, 8, (1), 2020Journal Article, 2020, DOI
  • Reuss, J.E., Forde, P.M., Immunotherapy for mesothelioma: Rationale and new approaches, Clinical Advances in Hematology and Oncology, 18, (9), 2020, p562-572Journal Article, 2020
  • Friedes, C., Mai, N., Fu, W., Hu, C., Hazell, S.Z., Han, P., McNutt, T.R., Forde, P.M., Redmond, K.J., Voong, K.R., Hales, R.K., Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy, Cancer, 126, (20), 2020, p4572-4583Journal Article, 2020, DOI
  • Linehan, A., Forde, P.M., Moving Immunotherapy into Early-Stage Lung Cancer, Cancer Journal (United States), 26, (6), 2020, p543-547Journal Article, 2020, DOI
  • Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D.C., White, J.R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., Rosner, S., Reuss, J.E., Smith, K.N., Adleff, V., Rodgers, K., Belcaid, Z., Rhymee, L., Levy, B., Feliciano, J., Hann, C.L., Ettinger, D.S., Georgiades, C., Verde, F., Illei, P., Li, Q.K., Baras, A.S., Gabrielson, E., Brock, M.V., Karchin, R., Pardoll, D.M., Baylin, S.B., Brahmer, J.R., Scharpf, R.B., Forde, P.M., Velculescu, V.E., Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer, Nature cancer, 1, (1), 2020, p99-111Journal Article, 2020, DOI
  • Shankar, B., Zhang, J., Naqash, A.R., Forde, P.M., Feliciano, J.L., Marrone, K.A., Ettinger, D.S., Hann, C.L., Brahmer, J.R., Ricciuti, B., Owen, D., Toi, Y., Walker, P., Otterson, G.A., Patel, S.H., Sugawara, S., Naidoo, J., Multisystem Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer, JAMA Oncology, 6, (12), 2020, p1952-1956Journal Article, 2020, DOI
  • Reuss, J.E., Anagnostou, V., Cottrell, T.R., Smith, K.N., Verde, F., Zahurak, M., Lanis, M., Murray, J.C., Chan, H.Y., McCarthy, C., Wang, D., White, J.R., Yang, S., Battafarano, R., Broderick, S., Bush, E., Brock, M., Ha, J., Jones, D., Merghoub, T., Taube, J., Velculescu, V.E., Rosner, G., Illei, P., Pardoll, D.M., Topalian, S., Naidoo, J., Levy, B., Hellmann, M.D., Brahmer, J.R., Chaft, J.E., Forde, P.M., Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer, Journal for ImmunoTherapy of Cancer, 8, (2), 2020Journal Article, 2020, DOI
  • Danilova, L., Anagnostou, V., Caushi, J.X., Sidhom, J.-W., Guo, H., Chan, H.Y., Suri, P., Tam, A., Zhang, J., Asmar, M.E., Marrone, K.A., Naidoo, J., Brahmer, J.R., Forde, P.M., Baras, A.S., Cope, L., Velculescu, V.E., Pardoll, D.M., Housseau, F., Smith, K.N., The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: A sensitive platform for monitoring antitumor immunity, Cancer Immunology Research, 6, (8), 2018, p888-899Journal Article, 2018, DOI
  • Marrone, K.A., Forde, P.M., Cancer immunotherapy in older patients, Cancer Journal (United States), 23, (4), 2017, p219-222Journal Article, 2017, DOI
  • Illei, P.B., Belchis, D., Tseng, L.-H., Nguyen, D., De Marchi, F., Haley, L., Riel, S., Beierl, K., Zheng, G., Brahmer, J.R., Askin, F.B., Gocke, C.D., Eshleman, J.R., Forde, P.M., Lin, M.-T., Clinical mutational profiling of 1006 lung cancers by next generation sequencing, Oncotarget, 8, (57), 2017, p96684-96696Journal Article, 2017, DOI
  • Anagnostou, V., Smith, K.N., Forde, P.M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., Hruban, C., Guthrie, V.B., Rodgers, K., Naidoo, J., Kang, H., Sharfman, W., Georgiades, C., Verde, F., Illei, P., Li, Q.K., Gabrielson, E., Brock, M.V., Zahnow, C.A., Baylin, S.B., Scharpf, R.B., Brahmer, J.R., Karchin, R., Pardoll, D.M., Velculescu, V.E., Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer, Cancer Discovery, 7, (3), 2017, p264-276Journal Article, 2017, DOI
  • Baik, C.S., Rubin, E.H., Forde, P.M., Mehnert, J.M., Collyar, D., Butler, M.O., Dixon, E.L., Chow, L.Q.M., Immuno-oncology clinical trial design: Limitations, challenges, and opportunities, Clinical Cancer Research, 23, (17), 2017, p4992-5002Journal Article, 2017, DOI
  • Anagnostou, V., Yarchoan, M., Hansen, A.R., Wang, H., Verde, F., Sharon, E., Collyar, D., Chow, L.Q.M., Forde, P.M., Immuno-oncology trial endpoints: Capturing clinically meaningful activity, Clinical Cancer Research, 23, (17), 2017, p4959-4969Journal Article, 2017, DOI
  • Naidoo, J., Cappelli, L.C., Forde, P.M., Marrone, K.A., Lipson, E.J., Hammers, H.J., Sharfman, W.H., Le, D.T., Baer, A.N., Shah, A.A., Albayda, J., Manno, R.L., Haque, U., Gutierrez, A.K., Bingham, C.O., Brahmer, J.R., Inflammatory arthritis: A newly recognized adverse event of immune checkpoint blockade, Oncologist, 22, (6), 2017, p627-630Journal Article, 2017, DOI
  • Forde, P.M., Scherpereel, A., Tsao, A.S., Use of Immune Checkpoint Inhibitors in Mesothelioma, Current Treatment Options in Oncology, 20, (2), 2019Journal Article, 2019, DOI
  • Marrone, K.A., Zhou, X., Forde, P.M., Purtell, M., Brahmer, J.R., Hann, C.L., Kelly, R.J., Coleman, B., Gabrielson, E., Rosner, G.L., Ettinger, D.S., A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer, Oncologist, 23, (7), 2018, p859-865Journal Article, 2018, DOI
  • Kumar, D., Mishra, A., Lisok, A., Kureshi, R., Shelake, S., Plyku, D., Sen, R., Doucet, M., De Silva, R.A., Mease, R.C., Forde, P.M., Jaffee, E.M., Desai, P., Ganguly, S., Gabrielson, E., Vaidya, D., Spangler, J.B., Nimmagadda, S., Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics, Proceedings of the National Academy of Sciences of the United States of America, 118, (37), 2021Journal Article, 2021, DOI
  • Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P.M., Sarantopoulos, J., Bedard, P.L., Lin, C.-C., Stephen Hodi, F., Wilgenhof, S., Santoro, A., Sabatos-Peyton, C.A., Longmire, T.A., Xyrafas, A., Sun, H., Gutzwiller, S., Manenti, L., Naing, A., Phase I/Ib clinical trial of sabatolimab, an anti"TIM-3 antibody, alone and in combination with spartalizumab, an anti"PD-1 antibody, in advanced solid tumors, Clinical Cancer Research, 27, (13), 2021, p3620-3629Journal Article, 2021, DOI
  • Reuss, J.E., Brigham, E., Psoter, K.J., Voong, K.R., Shankar, B., Ettinger, D.S., Marrone, K.A., Hann, C.L., Levy, B., Feliciano, J.L., Brahmer, J.R., Feller-Kopman, D., Lerner, A.D., Lee, H., Yarmus, L., Hales, R.K., D'Alessio, F., Danoff, S.K., Forde, P.M., Suresh, K., Naidoo, J., Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC, JTO Clinical and Research Reports, 2, (10), 2021Journal Article, 2021, DOI
  • Balaji, A., Hsu, M., Lin, C.T., Feliciano, J., Marrone, K., Brahmer, J.R., Forde, P.M., Hann, C., Zheng, L., Lee, V., Illei, P.B., Danoff, S.K., Suresh, K., Naidoo, J., Steroid-refractory PD-(L)1 pneumonitis: Incidence, clinical features, treatment, and outcomes, Journal for ImmunoTherapy of Cancer, 9, (1), 2021Journal Article, 2021, DOI
  • Lam, V.K., Forde, P.M., Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer, Journal of Thoracic Oncology, 15, (10), 2020, p1556-1558Journal Article, 2020, DOI
  • Naidoo, J., Cottrell, T.R., Lipson, E.J., Forde, P.M., Illei, P.B., Yarmus, L.B., Voong, K.R., Feller-Kopman, D., Lee, H., Riemer, J., Wang, D., Taube, J.M., Brahmer, J.R., Lin, C.T., Danoff, S.K., D'Alessio, F.R., Suresh, K., Chronic immune checkpoint inhibitor pneumonitis, Journal for ImmunoTherapy of Cancer, 8, (1), 2020Journal Article, 2020, DOI
  • Naing, A., Gainor, J.F., Gelderblom, H., Forde, P.M., Butler, M.O., Lin, C.-C., Sharma, S., Ochoa De Olza, M., Varga, A., Taylor, M., Schellens, J.H.M., Wu, H., Sun, H., Silva, A.P., Faris, J., Mataraza, J., Cameron, S., Bauer, T.M., A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors, Journal for ImmunoTherapy of Cancer, 8, (1), 2020Journal Article, 2020, DOI
  • Chen, X., Sheikh, K., Nakajima, E., Lin, C.T., Lee, J., Hu, C., Hales, R.K., Forde, P.M., Naidoo, J., Voong, K.R., Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies, Oncologist, 26, (10), 2021, pe1822-e1832Journal Article, 2021, DOI
  • Forde, P.M., Kelly, R.J., Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer, Journal of Thoracic Oncology, 8, (6), 2013, p673-684Journal Article, 2013, DOI
  • Zeidan, A.M., Forde, P.M., Streiff, M.B., Diagnosis, Treatment, and Prevention of Cancer-Associated Venous Thromboembolism, Abeloff's Clinical Oncology: Fifth Edition, 2013, p542-561Book Chapter, 2013
  • Forde, P.M., Kelly, R.J., Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies, Oncologist, 18, (7), 2013, p823-832Journal Article, 2013, DOI
  • Zeidan, A., Faltas, B., Forde, P., Subhawong, A., Bello, C., Bolaños-Meade, J., Sequential occurrence of a splenic marginal zone lymphoma, extranodal MALT lymphoma, and hodgkin lymphoma, Clinical Lymphoma, Myeloma and Leukemia, 13, (4), 2013, p496-498Journal Article, 2013, DOI
  • Forde, P.M., Ettinger, D.S., Targeted therapy for non-small-cell lung cancer: Past, present and future, Expert Review of Anticancer Therapy, 13, (6), 2013, p745-758Journal Article, 2013, DOI
  • Boikos, S.A., Forde, P.M., Chatterjee, S., Hann, C.L., Tumor lysis syndrome in limited-stage small-cell lung cancer, Journal of Thoracic Oncology, 8, (7), 2013Journal Article, 2013, DOI
  • Forde, P.M., Reiss, K.A., Zeidan, A.M., Brahmer, J.R., What lies within: Novel strategies in immunotherapy for non-small cell lung cancer, Oncologist, 18, (11), 2013, p1203-1213Journal Article, 2013, DOI
  • Forde, P.M., Rudin, C.M., Crizotinib in the treatment of non-small-cell lung cancer, Expert Opinion on Pharmacotherapy, 13, (8), 2012, p1195-1201Journal Article, 2012, DOI
  • Lefter, S., Forde, P., Nashat, H., Moylan, E., Yacoob, Y., A 27-year-old man with diplopia, fatiguable ptosis and rash: A rare presentation of angiocentric T cell lymphoma with lymphomatoid vasculitis, BMJ Case Reports, 2011Journal Article, 2011, DOI
  • Forde, P., Murphy, C., O'Sullivan, C., Carney, D., Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer, Irish Journal of Medical Science, 180, (1), 2011, p283-284Journal Article, 2011, DOI
  • Rock, C., Brady, D., Forde, P., Lucey, P., Horgan, M., Leptospirosis: a globally increasing zoonotic disease., BMJ case reports, 2010, 2010Journal Article, 2010, DOI
  • Forde, PM, Rock, K, Wilson, G, O'Byrne, KJ, Ipilimumab-induced Immune-related Renal Failure - A Case Report, ANTICANCER RESEARCH, 32, (10), 2012, p4607-4608Journal Article, 2012

Recognition

  • ECOG-ACRIN Young Investigator Award 2023
  • Daniel C. Ihde Award for Medical Oncology, International Association for the Study of Lung Cancer 2022
  • Member of European Society of Medical Oncology, American Association for Cancer Research, American Society of Clinical Oncology